| 15.19 0.2 (1.33%) | 04-23 09:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 19.72  |
1-year : | 22.19 |
| Resists | First : | 16.89 |
Second : | 19 |
| Pivot price | 14.98 |
|||
| Supports | First : | 13.47 | Second : | 11.21 |
| MAs | MA(5) : | 14.28 |
MA(20) : | 15.29 |
| MA(100) : | 21.62 |
MA(250) : | 25.41 |
|
| MACD | MACD : | -1.1 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 29.8 |
D(3) : | 19 |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 39.5 | Low : | 13.47 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ZLAB ] has closed below upper band by 49.8%. Bollinger Bands are 34.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.28 - 15.36 | 15.36 - 15.42 |
| Low: | 14.31 - 14.39 | 14.39 - 14.46 |
| Close: | 14.86 - 14.99 | 14.99 - 15.11 |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
Mon, 22 Apr 2024
Zai Lab (NASDAQ:ZLAB) Shares Gap Up to $14.07 - MarketBeat
Sun, 21 Apr 2024
Why Earnings Season Could Be Great for Zai Lab (ZLAB) - Yahoo Movies UK
Thu, 18 Apr 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB - The Globe and Mail
Wed, 17 Apr 2024
Zai Lab Limited (NASDAQ:ZLAB) Stock Position Lowered by Genesis Investment Management LLP - MarketBeat
Tue, 16 Apr 2024
A Risky Bet: Zai Lab's Uncertain Future (NASDAQ:ZLAB) - Seeking Alpha
Fri, 29 Mar 2024
Lacklustre Performance Is Driving Zai Lab Limited's (NASDAQ:ZLAB) 29% Price Drop - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 99 (M) |
| Shares Float | 888 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 44.3 (%) |
| Shares Short | 3,870 (K) |
| Shares Short P.Month | 4,060 (K) |
| EPS | -3.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.18 |
| Profit Margin | -125.5 % |
| Operating Margin | -188.4 % |
| Return on Assets (ttm) | -20.9 % |
| Return on Equity (ttm) | -36.4 % |
| Qtrly Rev. Growth | 5.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.68 |
| EBITDA (p.s.) | -3.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -198 (M) |
| Levered Free Cash Flow | -95 (M) |
| PE Ratio | -4.29 |
| PEG Ratio | 0 |
| Price to Book value | 1.83 |
| Price to Sales | 5.57 |
| Price to Cash Flow | -7.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|